author-photo

Kevin Kalinsky

Columbia University
Columbia University Medical Center

241

Papers

2447

Citations

Citation Trend

Filter By

Papers (168) Sort By

Journal Conference Others

Abstract GS3-06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
Abstract PS5-12: Preliminary correlative analysis of clinical outcomes with PIK3CA mutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

2021 Cancer Cell
Show All
- Source
- Cite
- Save
Citations (5)
Abstract PS12-20: A dose escalation study of the novel oral SERD-ZN-c5 in women with ER-positive, HER2-negative advanced/metastatic breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract SP012: Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine signaling inhibitors

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Changes in diffuse-optical-tomography images during early stages of neoadjuvant chemotherapy correlate with tumor response in different breast cancer subtypes.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 645: Network-based assessment of HDAC6 activity is highly predictive of pre-clinical and clinical responses to the HDAC6 inhibitor ricolinostat

2021
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PS11-11: Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Abstract OT-36-01: Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients withPIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2- LA/MBC)

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)